Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 29 citing articles:

Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients
Francesco Sabbatino, Luigi Liguori, Giovanna Polcaro, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 7295-7295
Open Access | Times Cited: 74
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, et al.
Cancer Treatment Reviews (2022) Vol. 113, pp. 102499-102499
Closed Access | Times Cited: 58
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy
Luke Maggs, Ananthan Sadagopan, Ali Sanjari Moghaddam, et al.
Trends in cancer (2021) Vol. 7, Iss. 12, pp. 1089-1101
Open Access | Times Cited: 44
Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy
Xiaonan Zhang, Tobias Sjöblom
Pharmaceuticals (2021) Vol. 14, Iss. 1, pp. 57-57
Open Access | Times Cited: 43
Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I
Valentina Ferrari, Antonino Lo Cascio, Alessia Melacarne, et al.
Cancer Cell (2023) Vol. 41, Iss. 10, pp. 1717-1730.e4
Open Access | Times Cited: 18
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade
Pierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000733-e000733
Open Access | Times Cited: 40
Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients
Maria‐Filothei Lazaridou, Evamaria Gonschorek, Chiara Massa, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 34
Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy
Silvia D’Amico, Patrizia Tempora, Ombretta Melaiu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
Kuen Kuen Lam, Siew Heng Wong, Peh Yean Cheah
Cells (2023) Vol. 12, Iss. 4, pp. 631-631
Open Access | Times Cited: 12
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
Saud Almawash
Cancers (2025) Vol. 17, Iss. 5, pp. 880-880
Open Access
Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases—Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway
Chiara Massa, Yuan Wang, Nico Marr, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6736-6736
Open Access | Times Cited: 10
Interplay between B7–H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma
Giulia Cattaneo, Marco Ventin, Shahrzad Arya, et al.
Cancer Letters (2024) Vol. 587, pp. 216713-216713
Open Access | Times Cited: 3
Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma
Maria‐Filothei Lazaridou, Chiara Massa, Diana Handke, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 9, pp. 2690-2690
Open Access | Times Cited: 25
Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors
Hinrich Abken
Human Gene Therapy (2021) Vol. 32, Iss. 19-20, pp. 1011-1028
Open Access | Times Cited: 21
Immunoinformatics Strategy to Develop a Novel Universal Multiple Epitope-Based COVID-19 Vaccine
Nizar A. Khamjan, Mohtashim Lohani, Mohammad Faheem Khan, et al.
Vaccines (2023) Vol. 11, Iss. 6, pp. 1090-1090
Open Access | Times Cited: 8
Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo
Gitte Holmen Olofsson, Agnete W.P. Jensen, Manja Idorn, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 11, pp. 3816-3816
Open Access | Times Cited: 22
Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
Vallì De Re, Laura Caggiari, Ombretta Repetto, et al.
Journal of Clinical Medicine (2019) Vol. 8, Iss. 10, pp. 1596-1596
Open Access | Times Cited: 20
Biomarkers for Immunotherapy of Cancer
Magdalena Thurin, Alessandra Cesano, Francesco M. Marincola
Methods in molecular biology (2019)
Closed Access | Times Cited: 20
Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy
Christoforos Vaxevanis, Michael Bachmann, Barbara Seliger
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 8, pp. e009774-e009774
Open Access | Times Cited: 2
Harnessing photo-induced processes for the fabrication and application of functional conjugated and conducting polymer-based materials
Michael Alowakennu, Ahmed Olalekan Omoniyi, Onome Ejeromedoghene, et al.
Journal of Molecular Structure (2023) Vol. 1292, pp. 136149-136149
Closed Access | Times Cited: 6
Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models
Karolina Žilionytė, Ugnė Bagdzevičiūtė, Agata Mlynska, et al.
Cancer Immunology Immunotherapy (2022) Vol. 71, Iss. 11, pp. 2691-2700
Open Access | Times Cited: 9
Resolving the Heterogeneous Tumor-Centric Cellular Neighborhood through Multiplexed, Spatial Paracrine Interactions in the Setting of Immune Checkpoint Blockade
Rachel L.G. Maus, Alexey A. Leontovich, Raymond M. Moore, et al.
Cancer Research Communications (2022) Vol. 2, Iss. 2, pp. 78-89
Open Access | Times Cited: 7
Cancer Immunotherapy: Diverse Approaches and Obstacles
Seyed Amir Sanatkar, Arash Heidari, Nima Rezaei
Current Pharmaceutical Design (2022) Vol. 28, Iss. 29, pp. 2387-2403
Closed Access | Times Cited: 6
Cancer Immunology: Immune Escape of Tumors—Expression and Regulation of HLA Class I Molecules and Its Role in Immunotherapies
Yuan Wang, Simon Jasinski‐Bergner, Claudia Wickenhauser, et al.
Advances in Anatomic Pathology (2022) Vol. 30, Iss. 3, pp. 148-159
Closed Access | Times Cited: 6
Adaptive and Innate Cytotoxic Effectors in Chronic Lymphocytic Leukaemia (CLL) Subjects with Stable Disease
Valentina Rubino, Flavia Carriero, Anna Teresa Palatucci, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9596-9596
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top